Elan Corporation, plc (ADR)  

(Public, NYSE:ELN)   Watch this stock  
Find more results for ELN
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E 0.00
Div/yield     -
EPS 4.28
Shares 514.98M
Beta     -
Inst. own 64%

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -28.40% -186350.00%
Operating margin -8.85% -226800.00%
EBITD margin - -95900.00%
Return on average assets -2.45% -21.96%
Return on average equity 510.79% -52.49%
Employees 245 -
CDP Score - -


Treasury Building Lower Grand Canal Street, Dublin 2
+353-1-7094000 (Phone)
+353-1-7094700 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Elan Corporation, plc (Elan) is a biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. On February 6, 2013, the Company announced that it has entered into an asset purchase agreement with Biogen Idec to transfer to Biogen Idec all Tysabri IP and other assets related to Tysabri. As of 31 December 2012, there were approximately 72,700 patients on Tysabri therapy worldwide. On December 20, 2012, the Company completed the separation of a substantial portion of its drug discovery business platform (the Prothena Business) into a new, publicly traded company, Prothena Corporation, plc (Prothena). In December 2013, Perrigo Company acquired Elan Corporation Plc.